The effect of 1,25-dihydroxyvitamin D3 on adenylate cyclase responsiveness was studied in the clonal osteogenic sarcoma cell line, UMR 106-06, which responds to several bone active hormones. 1,25-dihydroxyvitamin D3 treatment had no consistent effect on basal formation of cyclic AMP in intact cells, but the responses to parathyroid hormone, isoproterenol, prostaglandin E2, salmon calcitonin and the plant diterpene, forskolin, were all attenuated, by up to 90%. 
INTRODUCTION
Receptors for 1,25(OH)2D3 have been identified in many cell types (for review see Eisman, 1983) . Although in many respects 1,25(OH)2D3 behaves as a steroid hormone, in some targets its physiological actions are similar to those of hormones which act through cyclic AMP. This is the case in bone, in which both 1,25(OH)2D3 and PTH promote bone resorption (Raisz et al., 1972) . Whereas PTH increases cyclic AMP formation as an important early event in its action (Chase et al., 1969) , 1 ,25(OH)2D3 has no known direct effect upon cyclic AMP generation (Wong et al., 1977) . Their common physiological effects prompted studies of interactions between these two hormones in their early effects on cells. Wong et al., (1977) showed that treatment of isolated bone cells with 1,25(OH)2D3 resulted in refractoriness to stimulation of cyclic AMP formation by PTH, but not by calcitonin. The refractoriness was evident within 6 h of treatment, and complete within 24 h. This was confirmed in later experiments in which refractoriness to PGE2 was also demonstrated after 1,25(OH)2D3 treatment (Kent et al., 1980) , and other workers noted refractoriness to PTH in 1,25(OH)2D3-treated bone cells (Crowell et al., 1981) . Previous data in this area had been conflicting, in that 1,25(OH)2D3 had been found by some to increase cyclic AMP responsiveness (Mahgoub & Sheppard, 1975) and by others to have no effect (Kakuta et al., 1975; Peck & Dowling, 1976; Herrman-Erlee et al., 1980; Lieberherr et al., 1980) . Recent observations in clonal osteogenic sarcoma cells (Catherwood, 1985) and in a human monocyte line (Rubin & Catherwood, 1984) revealed that 1 ,25(OH)2D3 treatment of those cells resulted in diminished responsiveness to PTH and to isoproterenol respectively.
In the present work we have investigated the effect of 1,25(OH)2D3 treatment on hormonal responses in a clonal osteogenic sarcoma cell line of rat origin, UMR 106-06 (Forrest et al., 1985) . This line, a subclone derived from UMR 106 , responds to PTH, PGE2, calcitonin and isoproterenol with an increase in cyclic AMP. The results show that 1,25(OH)2D3 treatment leads to refractoriness to each of those hormones, and that this effect of 1,25(OH)2D3 is likely to be mediated through its receptor. Furthermore, the mechanism of action of 1,25(OH)2D3 has been investigated, and the lack of involvement of nucleotide regulatory subunits is consistent with an action of the steroid beyond this component of the adenylate cyclase complex. (Forrest et al., 1985) were grown in 75 cm2 plastic culture flasks (Miles Laboratories, Naperville, IL, U.S.A.) in modified Eagle's minimal essential medium containing 10% (v/v) foetal calf serum, gentamycin (80 mg/l) and minocyclin (1 mg/1) and were incubated at 37°C in C02/air (1:19). Replicate subcultures were performed, and cells were harvested with 0.0125% trypsin and 0.5 mM-disodium EDTA in phosphate-buffered saline, pH 7.4. Cells were seeded into 12-well tissue culture dishes (4.5 cm2/well; Flow Laboratories) at approx. 5 x 104 cells/well. After the cells had become attached to the wells overnight, vitamin D compounds dissolved in ethanol or vehicle were added in fresh medium containing 2% (v/v) foetal calf serum treated with charcoal, which decreases concentrations of endogenous 1,25(OH)2D3 by 90% (Eisman et al., 1980 (Salomon et al., 1974; Michelangeli et al., 1984 (Lamp et al., 1981) . Cells subcultured in wells were washed with phosphate-buffered saline, pH 7.4. Synthetic salmon calcitonin was labelled with Na1251 as previously described (Hunt et al., 1977) using 2 ,ug of chloramine-T for 10 s. Purified labelled hormone was stored in acetone/100 acetic acid (1:4, v/v) in small samples.
Incubations were carried out in a total volume of 500 m1l
[400 ,ul of medium containing 0.1 % (w/v) bovine serum albumin, 50 #tl of '251-labelled salmon calcitonin (105 c.p.m./well) and 50 ,1 of varying amounts of unlabelled salmon calcitonin] at 37°C for 60 min with continuous agitation. The medium was then aspirated and the cells were washed twice with phosphate-buffered saline, pH 7.4 at 4 'C. The reaction was terminated by solubilizing cells with 100 ,1 of 0.1 M-NaOH, and their radioactivity was measured in a Packard Auto-Gamma scintillation spectrometer, model 51 10.
Preparation of cyc-S49 membranes
Preparation of cyc-S49 membranes, extraction of UMR 106-06 N-component and reconstitution assay were performed as described (Ross et al., 1977; Iyengar et al., 1981; Rich et al., 1984) , with minor modifications. Cyc-S49 cells (clone 94.15.1), obtained from the University of California Cell Repository, San Francisco, CA, U.S.A., were grown in Dulbecco's modified Eagle's medium containing 10% (v/v) foetal calf serum at 37 'C in C02/air (1:19) in 175 cm2 plastic culture flasks (Nunc, Roskilde, Denmark). Cells were harvested at low speed (1000 rev./min, 10 min), and washed with phosphate-buffered saline, pH 7.4. Cells resuspended in 150 mM-NaCl/2 mM-MgCl2/1 mM-EDTA/1 mM-2-mercaptoethanol/20 mM-Hepes, pH 7.4, were then lysed by nitrogen cavitation [2.76 MPa (400 lbf/in2) for 20 min at 4 'C] in a Parr nitrogen disruption apparatus (Parr Instrument Co., Moline, IL, U.S.A.), and centrifuged at 750 g for 5 min. The supernatants were then centrifuged at 43 000 g for 20 min at 4 'C. The pellets were resuspended in a mixture of 10% (w/v) sucrose/ 2 mM-MgCl2/ 1 mM-EDTA/ 1 mM-2-mercaptoethanol/ 10%0 (v/v) glycerol/ 25 mM-Hepes/NaOH, pH 8.0, at a protein concentration of 2 mg/ml and stored at -70 'C until use.
Extraction of UMR 106-06 cell membrane nucleotide regulatory activity UMR 106-06 cell membranes with or without 1,25(OH)2D3 pretreatment were prepared according to the procedure used for cyc-S49 cell membranes. The pellets from the 43 000 g centrifugation were resuspended and stirred in 50 mM-NaCl/1 mM-EDTA/1 mM-2-mercaptoethanol/1000 (w/v) sucrose/1i/0 (w/v) sodium cholate/25 mM-Hepes/NaOH, pH 8.0, at 4°C for 30 min. The suspension was centrifuged at 100000 g for 60 min at 4 'C. Protein concentrations ofthe supernatants of both treatment groups were adjusted to 500 ,ug/ml with the same buffer. These supernatants were incubated at room temperature for 20 min to inactivate their adenylate cyclase catalytic unit activi4y. Reconstitution assays of UMR cell membrane nucleotide regulatory unit stimulatory (N) activity Reconstitution was carried out by incubating cyc-S49 membranes with diluted cholate extract of UMR 106-06 cell membranes at 32.5°C for 10 min in the presence of 25 mM-Hepes/NaOH (pH 8.0)/2 mM-MgCl2/1 mM-EDTA/0.5 mM-ATP/0.1 mM-GTP/0.25% cholate. Reconstituted mixture (20 ,ul) (Salomon et al., 1974 (Fig. 1) . The half-maximally effective concentration of 1,25(OH)2D3 for this response was 0.1 nm. 24,24-Difluoro-1,25(OH)2D3 was slightly more effective than 1,25(OH)2D3 itself, with half maximal effectiveness at 0.03 nm. This is consistent with its known greater biological activity upon chick duodenum (Corradino et al., 1980) , and approximately equal affinity with that of 1,25(OH)2D3 for the receptor in breast cancer cells Viai / compoud (nM Fig. 1 (Eisman et al., 1983) . On the other hand, the difluoro compound was found to be less effective than 1,25(OH)2D3 in promoting bone resorption (Stem et al., 1981) . Subtle differences in biological activity of the difluoro compound in different assay systems are thought to be related to its resistance to metabolism in the C-24 position (Eisman et al., 1983 (Fig. 2) . Diminished responses to salmon calcitonin, PGE2 and forskolin only became apparent by day 4. In no case was any significant attenuation of hormone response noted within 24 h, which contrasts with previous observations in mixed bone cells in which effects were usually complete by 24 h (Wong et al., 1977; Kent et al., 1980; Crowell et al., 1981) .
Effect of 1,25(OH)2D3 on responsiveness of UMR 106-06 cells to hormones
Treatment of UMR 106-06 cells with 1,25(OH)2D3 (10 nM) for 5 days resulted in decreased cyclic AMP generation in response to maximum hormone concentrations (Fig. 3) . In the case of PTH this was consistently associated with some decrease in sensitivity, but no such effect was obtained with calcitonin or PGE2. In the experiment of Fig. 3, 1 (Forrest et al., 1985) , and since receptor studies with calcitonin can be carried out more reliably than with PTH, the binding of biologically active labelled salmon calcitonin to intact UMR 106-06 cells was measured in cells with or without treatment with 1,25(OH)2D3 for 5 days. The results (Fig. 4) show that treatment had no effect on the binding ofcalcitonin to the cells, indicating that any effect upon the cyclic AMP response to calcitonin took place beyond the hormone receptor. Effect of treatment of UMR 106-06 cells with IAP on the response to 1,25(OH)2D3
It seemed likely that the effect of 1,25(OH)2D3 on hormone response occurred at some site beyond hormone-receptor interaction. Adenylate cyclase activation requires the participation of nucleotide stimulatory (Ne) and nucleotide inhibitory (Ni) units. Stimulation results from activation of N. (Cooper et al., 1979) , and inhibition is mediated by Ni (Hildebrandt et al., 1982) .
IAP, the active protein of Bordetella pertussis toxin, has been used effectively as an inhibitor of Ni unit activity (Katada & Ui, 1982; Bokoch et al., 1983; Michelangeli et al., 1984; Asano et al., 1984) . Since it was possible that 1,25(OH)2D3 treatment led to enhanced Ni unit activity, thereby decreasing cyclic AMP response, experiments were carried out to test this possibility. UMR 106-06 cells were treated with IAP (1.6 x 10-10 M), and cyclic AMP responses to PTH were measured in cells with or without 5 days pre-treatment with 1,25(OH)2D3. IAP treatment had no significant effect on the ability of 1,25(OH)2D3 to impair responsiveness to PTH ( Table 2 ). The conditions used for treatment with IAP were those which we had shown in other cells to be effective in blocking Ni unit activity (Michelangeli -et al., 1984) . their content of Ns, using the ability of the extracts to confer adenylate cyclase responsiveness on membrane preparation of cyc-S49 mouse lymphoma cells, which are deficient in N. unit activity (Bourne et al., 1975) . The results (Table 3) showed that 1,25(OH)2D3 treatment did not lead to any loss of total N. unit activity from UMR 106-06 cells as measured in the reconstitution assay. Under these conditions no adenylate cyclase activity or isoproterenol response could be detected in cyc-S49 membranes without addition of cholate extracts containing N. unit activity. 
DISCUSSION
The ability of 1,25(OH)2D3 treatment to give rise to 'heterologous desensitization' to PTH and PGE2 in mixed bone cell cultures has been noted previously (Wong et al., 1977; Kent et al., 1980) , but there has been no study of the specificity of this effect or its mechanism. The experiments reported here in a clonal line of osteoblast phenotype show that the vitamin D hormone exerts its effects on cyclic AMP responsiveness whatever the agent used to enhance cyclic AMP formation. The experiments were carried out under conditions ofmaximum inhibition of cyclic nucleotide phosphodiesterase, so effects of 1 ,25(OH)2D3 on that enzyme cannot contribute to the results obtained. The time taken for appearance of reduced hormone response was appreciably longer than that for mixed bone cell cultures, in which effects were seen as early as 6 h after starting treatment (Wong et al., 1977) . It is clearly shown in this work that the response to 1,25(OH)2D3 is a sensitive one, and furthermore that the relative effectiveness of various metabolites and analogues of vitamin D reflects their abilities to compete for binding to the 1,25(OH)2D3 receptor (Eisman, 1983) . Thus it seems likely that the effect of 1,25(OH)2D3 is mediated through the receptor for this steroid. It is not yet possible to identify the site of action of 1,25(OH)2D3 on the adenylate cyclase complex which leads to refractoriness to hormones and forskolin. Our studies of calcitonin binding showed that 1,25(OH)2D3 treatment had no effect on calcitonin receptor number or affinity. Although specific binding of the other agonists to their respective receptors was not measured, the fact that refractoriness was induced to a range of stimulating agents made a hormone-receptor mechanism unlikely. It should be pointed out however, that in the case of PTH, half maximally effective hormone concentration was consistently decreased by 1,25(0H)2D3 treatment, by at least 10-fold. Thus it is possible that for PTH there is an additional component of the 1,25(OH)2D3 effect, perhaps through a decrease in the affinity of PTH for its receptor.
This-cannot be excluded at this stage because methods to document this are not adequate at present. Forskolin, which has been a useful agent in the study of adenylate cyclase control, is thought to act directly on the catalytic component of adenylate cyclase (Pfeuffer & Metzger, 1982) . There is some evidenre, however, for a possible role of nucleotide regulatory prptein in forskolin action (Daly et al., 1982; Schneyer et al., 1983 ). The present observations are similar to those made in a human monocyte line, in which 1,25(OH)2D3 treatment induced refractoriness both to forskolin and isoproterenol (Rubin & Catherwood, 1984) . Because of the possibility that forskolin might act directly on nucleotide regulatory components as well as catalytic unit of adenylate cyclase, it was necessary to exclude the possibility that the 1,25(OH)2D3 effect operated through such a mechanism.
Experiments were therefore carried out to determine whether enhanced Ni unit or diminished N, unit activities could be responsible for the effect of 1,25(OH)2D3. The present results were not consistent with a mechanism operating directly through N. or Ni. They do not exclude the possibility that 1,25(OH)2D3 treatment might result in a lesser activity of a specific subgroup of N, units, although we think this unlikely since it is not known whether such subgroups exist. Some observations of actions of steroid hormone action indicate possible effects on nucleotide regulatory proteins. For example, in glucocorticoid-deficient animals, coupling of adenylate cyclase was reduced, consistent with a requirement of glucocorticoids for normal N, unit activity (Davies et al., 1981) . On the other hand, treatment of rabbits with luteinizing hormone led to a decrease in corpus luteum Ns activity (Kirchick & Birnbaumer, 1983) . At present we conclude, therefore, that the ability of 1,25(OH)2D3 to decrease cyclic AMP response to several hormones and forskolin results from an effect of the steroid hormone beyond hormone receptor and nucleotide regulatory proteins, and perhaps directed at the catalytic unit of the adenylate cyclase itself. One possible mechanism for this is that 1,25(OH)2D3 alters intracellular availability of Mg2+ to the adenylate cyclase complex, thereby altering responses to the hormones and forskolin. This suggestion is made because of the importance of Mg2+ in the activation of adenylate cyclase by hormones and forskolin . 1,25(OH)2D3 receptors have been identified in many tissues, and in cells derived from many organs in the body (Eisman, 1983) . The possibility that 1,25(OH)2D3 is capable of affecting a process as fundamental as that of cyclic AMP generation, and to do so in a sensitive manner, points to important general functions of the vitamin D hormone.
